Study Explains Why MuSK MG Patients Relapse After Rituxan Therapy

A recent study by researchers from Yale University furthers understanding about why certain myasthenia gravis (MG) patients who were treated with Rituxan (rituximab) may relapse. Findings of the study, “Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis,” were published at The Journal of Clinical…

Cognitive Behavioral Therapy Could Help MG Patients with Anxiety, Depression or Insomnia

Cognitive Behavioral Therapy (CBT) should be considered as a first-line treatment for myasthenia gravis (MG) patients who also suffer from anxiety, depression, or insomnia disorders, a new study urges. The study, “Cognitive-Behavioral Therapy for Psychiatric Comorbidity in a Case of Muscle-Specific Kinase–Positive Myasthenia Gravis,” appeared in the journal…

Alexion Receives Extended Patent in Japan for Soliris (Eculizumab)

The Japanese Patent Office (JPO) has issued a new patent for the composition of eculizumab, marketed as Soliris by Alexion Pharmaceuticals, and its pharmaceutical formulations until 2027. Alexion is currently pursuing a patent for additional indications of Soliris, including for the treatment of anti-acetylcholine receptor (AchR) antibody-positive generalized…

argenx Doses First Subject in Study Evaluating Subcutaneous ARGX-113 for Autoimmune Diseases

The first participant has been dosed in a Phase 1 clinical trial evaluating  argenx‘s subcutaneous formulation of ARGX-113 in healthy volunteers. ARGX-113 is an investigational antibody designed for the treatment of patients with severe autoimmune diseases associated with high levels of harmful immunoglobulin G (IgG) antibodies, such as myasthenia gravis (MG).

2021 Myasthenia Gravis Survey Results

BioNews Survey Infographic

Myasthenia Gravis News conducted a survey from Feb. 11-March 28 to gain greater insight into the characteristics of the MG community and disease management. Results of the survey have now been published. Click on the image to view the infographic, and click here to read the story.